blocking antibody. These data support that MR activation in human endothelial cells promotes ICAM-1-mediated leukocyte-EC adhesion, an important step in early atherosclerosis lesion formation. To further explore the mechanisms for MR-mediated EC activation, we now demonstrate that MR activation up-regulates VCAM-1 and E-selectin mRNA expression (2 and 3.5 fold respectively), whereas P-selectin is not regulated by MR. We also further explored the mechanism of MRmediated regulation of endothelial ICAM-1 expression. In transient transfection experiments performed in HUVEC, we have shown that aldosterone is able to activate (2 fold) a 3 Kb promoter region upstream the transcription start site of human ICAM-1 gene. Coincubation with spironolactone was able to inhibit the effect of aldosterone, confirming the presence of elements responsive to signaling pathway(s) activated by MR. In order to localize and characterize MR responsive cis-element(s) and the corresponding transcription factor(s) binding to this regulatory region, five 5′deletion constructs of ICAM-1 promoter were subcloned in a vector upstream of the luciferase gene. Data of transcriptional activity showed the presence of regulatory element(s) required for ICAM-1 expression via MR in the promoter region between nt-872 and -1141. Bioinformatics analysis of this region revealed the presence of four different highly conserved regulatory elements: three SP1 binding sites, one NF-κB binding site, one AP1 binding site and one GRE/MRE. The role of these transcription factors in MR-mediated regulation of ICAM-1 expression was investigated using c-JUN and IKBα dominant negative constructs. Blocking of either c-Jun or NF-κB pathway resulted in a marked reduction of the aldosterone effect on ICAM-1 promoter activity, suggesting the involvement of these transcription factors. These studies explore the molecular mechanism for the proinflammatory effects of MR activation in the vasculature that may contribute to explain the protective effects of MR antagonists in clinical trials. Moreover to better understand the crosstalk between MR activation and ICAM1 in the development of atherosclerosis lesions, we developed a mouse model double KO for ApoE and ICAM1, where we are currently studying the pro-atherogenic effects of aldosterone.
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A prospective, open-label, parallel group, placebo-controlled study on 77 patients with elevated serum LDL-C and triglycerides was designed. Patients were randomly assigned to a control group receiving placebo (n = 15), two groups receiving orally rosuvastatin (10 and 20 mg/daily for 30 days n = 16 for each group), a group receiving BPF alone orally (1000 mg/daily for 30 days; n = 15) and a group receiving BPF (1000 mg/daily given orally) plus rosuvastatin (10 mg/daily for 30 days; n = 15).
Both doses of rosuvastatin and BPF reduced total cholesterol, LDL-C, the LDL-C/HDL-C ratio and urinary mevalonate in hyperlipidemic patients, compared to control group. The cholesterol lowering effect was accompanied by reductions of malondialdehyde, oxyLDL receptor LOX-1 and phosphoPKB, which are all biomarkers of oxidative vascular damage, in peripheral polymorphonuclear cells.
Addition of BPF to rosuvastatin significantly enhanced rosuvastatin-induced effect on serum lipemic profile compared to rosuvastatin alone, an effect associated to significant reductions of biomarkers used for detecting oxidative vascular damage, suggesting a multiaction synergistic potential for BPF in statin-taking patients. BPF may be an alternative therapeutic strategy for hyperlipidemia in patients with statin-induced side effects. The occurrence of Metabolic Syndrome (MS) represents an independent risk factor for developing cardiovascular disease states in patients suffering from type 2 diabetes mellitus. Moreover, both the size of LDL particles and liver dysfunction identified as nonalcoholic fatty liver disease (NAFLD) represent important biomarkers for the development of cardiometabolic risk in patients with MS. We studied the effect of bergamot polyphenolic fraction (BPF) in patients with MS and NAFLD. 107 patients were enrolled at the San Raffaele IRCCS (Rome). All of them showed ultrasonografic evidences of NAFLD and at least three out of five previous identified criteria for the diagnosis of MS. Patients were divided into two groups: one receiving placebo and the second receiving BPF 650 mg twice a day for 120 consecutive days. In the group receiving BPF 650 mg twice a day, a significant reduction of fasting plasma glucose, serum LDL cholesterol and triglycerides alongside with an increase of HDL cholesterol was found. This effect was accompanied by a significant reduction of both ultrasonographic and metabolic biomarkers of NAFLD as well as by a decrease of small dense LDL particles.
Overall, our data show that bergamot-deriving polyphenolic fraction given in patients with MS and NAFLD, leads to concomitant amelioration of the lipemic and glycemic serum profiles and to substantial reduction of liver steatosis. This effect, alongside with a reduction of pro-atherogenic small dense LDL and enhancement of anti-atherogenic high dense HDL, shed new light on the potential use of bergamot-extract for reducing cardiometabolic risk in patients with MS. doi:10.1016/j.ijcme.2015.05.015
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